In this episode of the Drug Solutions podcast, Chris Spivey, editorial director, and Meg Rivers, senior editor, interview Sean Tucker, PhD, chief scientific officer of Vaxart, on developing oral recombinant vaccines, including developing this type of vaccine and how it differs from injectable vaccines, an inside look into the manufacture for clinical trials, what pathogens oral recombinant vaccines may be a better treatment option for, longevity of protection, and how this type of vaccine could impact the pharmaceutical industry.